Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials

Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials

Background Patients with type 2 myocardial infarction (T2MI) and other mechanisms of nonthrombotic myocardial injury have an unmet therapeutic need. Eligibility for novel medical therapy is generally uncertain.Methods We predefined colchicine, eplerenone and ticagrelor as candidates for repurposing...

Full description

Bibliographic Details
Main Authors: Colin Berry, Kenneth Mangion, Robert Sykes, Michael Briscoe, Thomas Krysztofiak, Oliver Peck
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Open Heart
Online Access:https://openheart.bmj.com/content/8/1/e001633.full

Similar Items

Similar Items